Other Information
−Removed: Departure of Directors or Certain Officers;
−Removed: Election of Directors;
−Removed: Appointment of Certain Officers;
−Removed: Compensatory Arrangements of Certain Officers
−Removed: On June 1, 2025, the Company entered into a Consulting Agreement with Kujo Capital, LLC, a Wyoming limited liability company, pursuant to which Kujo Capital, LLC agrees to make available the services of Mr.
−Removed: Al Kucharchuk as Chief Financial Officer of the Company on a consultancy basis.
−Removed: Effective as of August 11, 2025, Mr.
−Removed: Tim Rotolo resigned as the Chief Financial Officer of the Company and the board of directors of the Company appointed Mr.
−Removed: Al Kucharchuk to serve as the Chief Financial Officer of the Company, to fill the vacancy created by Mr.
−Removed: Tim Rotolo’s resignation.
−Removed: Kucharchuk serves as Chief Financial Officer of Cero Therapeutics, Inc (Nasdaq:CERO).
−Removed: Previously, he has served as the Chief Financial Officer of Theralink Technologies, Inc.
−Removed: (“Theralink”) (OTCMKTS:
−Removed: THER) from May 2023 until May 2024 also served as President and Chief Financial Officer of Theralink from February 2016 until June 2020, as Chief Executive Officer of Theralink from November 2019 until June 2020 and as Acting Chief Financial Officer of Theralink from June 2020 to September 2020.
−Removed: He has served on the Board of Directors of Theralink since June 2020.
−Removed: Kucharchuk also served as Chief Executive Officer and Chief Financial Officer of OncBioMune, Inc.
−Removed: (“OBMP”) prior to Theralink’s acquisition of OBMP.
−Removed: Kucharchuk served as the Chairman and Chief Operating Officer Adhera Therapeutics, Inc.
−Removed: ATRX) from July 2020 until September 2022 and its Chief Operations Officer from October 2022 to September 2024.
−Removed: Kucharchuk is a graduate of Louisiana State University and Tulane University’s Freeman School of Business, where he earned an MBA with a Finance Concentration.
Insider Trading Arrangements and Policies
−Removed: During the six months ended June 30, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f)
−Removed: of the Exchange Act) adopted or terminated a “Rule 10b5-1
−Removed: trading arrangement” or “non-Rule
−Removed: trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the nine months ended September 30, 2025, none of the Company’s directors or officers (as defined in
+Added: Rule16a-1(f)of
+Added: the Exchange Act) adopted or terminated a “Rule10b5-1trading arrangement” or
+Added: “non-Rule10b5-1trading
+Added: arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
1 unchanged sentence
Amended and Restated Memorandum and Articles of Association of the Company, dated December 23, 2024 (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on December 26, 2024 and incorporated by reference herein).
−Removed: Consulting Agreement, dated June 1, 2025.
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
10 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, formatted in Inline XBRL.
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline XBRL.
Filed herewith.
2 unchanged sentences
RANGE CAPITAL ACQUISITION CORP.
−Removed: Date August 14, 2025
+Added: Date November 10, 2025
/s/ Tim Rotolo
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.